Five years of thoracic endoscopy unit activity on lung cancer staging: how teamwork can improve the outcomes.
EBUS-TBNAb
EUS-FNAb
Mediastinal lymph nodes
lung cancer
lung cancer staging
thoracic endoscopy
Journal
Mediastinum (Hong Kong, China)
ISSN: 2522-6711
Titre abrégé: Mediastinum
Pays: China
ID NLM: 101731833
Informations de publication
Date de publication:
2021
2021
Historique:
received:
24
07
2020
accepted:
30
03
2021
entrez:
4
2
2022
pubmed:
5
2
2022
medline:
5
2
2022
Statut:
epublish
Résumé
Regarding the staging of mediastinal lymph nodes before lung cancer surgery, Endobronchial Ultrasound Transbronchial Needle Aspirations (EBUS-TBNA) have proven to be highly sensitive and specific as well as safe. Endoscopic Ultrasound Fine Needle Aspirations (EUS-FNA) plays an important role in the diagnosis and staging of thoracic diseases, including lung cancer. In this study we analysed all patients underwent endoscopic procedures in our endoscopic mediastinal ultrasound unit. Between January 2013 and February 2018, we performed a total of 929 endoscopic procedures, 432 EBUS-TBNA and 497 EUS-FNA. Biopsy was performed at the following mediastinal sites: station 7 in 642 cases, at stations 8 and 9 in 211 cases; at station 3P and 4L in 27 and 114 cases respectively; with EUS we were able to perform biopsy at station 5 in 52 cases. A total of 841 patients showed a diagnosis of cancer: non-small cell lung cancer (NSCLC) in 645 patients, SCLC in 190 patients, neuroendocrine tumour in 5 patients and one patient with mesothelioma. 88 patients were negative for cancer. In terms of sensitivity, specificity and accuracy, the association between EUS-FNAb and EBUS-TBNAb showed a better quality on diagnosis compared to single procedures. EUS-FNA and EBUS-TBNA are safe, feasible, and highly sensitive techniques. An endoscopic mediastinal ultrasound unit allows to perform a higher number of endoscopic procedures and improved the sensitivity and the accuracy of the minimally invasive hilar-mediastinal staging.
Sections du résumé
BACKGROUND
BACKGROUND
Regarding the staging of mediastinal lymph nodes before lung cancer surgery, Endobronchial Ultrasound Transbronchial Needle Aspirations (EBUS-TBNA) have proven to be highly sensitive and specific as well as safe. Endoscopic Ultrasound Fine Needle Aspirations (EUS-FNA) plays an important role in the diagnosis and staging of thoracic diseases, including lung cancer. In this study we analysed all patients underwent endoscopic procedures in our endoscopic mediastinal ultrasound unit.
METHODS
METHODS
Between January 2013 and February 2018, we performed a total of 929 endoscopic procedures, 432 EBUS-TBNA and 497 EUS-FNA. Biopsy was performed at the following mediastinal sites: station 7 in 642 cases, at stations 8 and 9 in 211 cases; at station 3P and 4L in 27 and 114 cases respectively; with EUS we were able to perform biopsy at station 5 in 52 cases.
RESULTS
RESULTS
A total of 841 patients showed a diagnosis of cancer: non-small cell lung cancer (NSCLC) in 645 patients, SCLC in 190 patients, neuroendocrine tumour in 5 patients and one patient with mesothelioma. 88 patients were negative for cancer. In terms of sensitivity, specificity and accuracy, the association between EUS-FNAb and EBUS-TBNAb showed a better quality on diagnosis compared to single procedures. EUS-FNA and EBUS-TBNA are safe, feasible, and highly sensitive techniques.
CONCLUSIONS
CONCLUSIONS
An endoscopic mediastinal ultrasound unit allows to perform a higher number of endoscopic procedures and improved the sensitivity and the accuracy of the minimally invasive hilar-mediastinal staging.
Identifiants
pubmed: 35118319
doi: 10.21037/med-20-53
pii: med-05-13
pmc: PMC8794365
doi:
Types de publication
Journal Article
Langues
eng
Pagination
13Informations de copyright
2021 Mediastinum. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/med-20-53). FF serves as an unpaid editorial board member for this journal from Apr 2020 to Mar 2022. The other authors have no conflicts of interest to declare.
Références
J Clin Oncol. 2005 Nov 20;23(33):8357-61
pubmed: 16219935
Rev Port Pneumol (2006). 2017 Mar - Apr;23(2):85-89
pubmed: 28196610
Transl Lung Cancer Res. 2014 Aug;3(4):225-33
pubmed: 25806304
Lung Cancer. 2017 Oct;112:156-164
pubmed: 29191588
J Thorac Dis. 2018 Aug;10(Suppl 22):S2601-S2610
pubmed: 30345097
Acta Oncol. 2001;40(1):79-82
pubmed: 11321666
Expert Rev Respir Med. 2019 Sep;13(9):863-870
pubmed: 31322034
Eur Radiol. 2016 Dec;26(12):4515-4523
pubmed: 26943133
Eur J Cardiothorac Surg. 2008 Jun;33(6):1124-8
pubmed: 18430581
Pulm Med. 2016;2016:1024709
pubmed: 27818796